Cardiovascular Risk Predictors in Patients With Psoriasis

Study Overview
=================
Brief Summary
-----------------
The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

Official Title
-----------------
Cardiovascular Risk Predictors in Patients With Psoriasis

Conditions
-----------------
Psoriasis, Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Written informed consent of the patient to participate in the study Exclusion Criteria: Age under 18 Pregnancy, lactation Very high cardiovascular risk Life-threatening, independently influencing prognosis and disabling diseases, Mental disorders that do not allow to give informed consent or answer questions adequately Refuse of the patient to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mild psoriasis<br> | |
| Moderate psoriasis<br> | |
| Severe psoriasis not receiving systemic therapy<br> | |
| Severe psoriasis receiving systemic therapy with genetic-engineering biological drugs<br> | |
| Patients without psoriasis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SCORE2-OP risk (Systematic COronary Risk Evaluation2- Older Person) | Increased cardiovascular risk over the follow-up period (from low to very high) | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall mortality | Number of deaths due to all reasons | 1 year | 
| Cardiovascular mortality | Number of deaths due to cardiovascular reasons | 1 year | 
| Progression of psoriasis (PASI) | Progression of severity of psoriasis according to PASI (The Psoriasis Area and Severity Index - 0 to 4, none to very severe) score | 1 year | 
| Quality of life (DLQI score) | Impact on quality of life by DLQI (Dermatology Life Quality Index - 0 to 30, no to extremely large impact) score | 1 year | 
| Hospitalization due to cardiovascular reasons | Number of patients hospitalized due to cardiovascular reasons | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psoriasis, cardiovascular risk, risk factors